Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vamorolone
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Santhera Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Santhera Secures Agreement with GEN for the Distribution of Agamree in Turkiye
Details : The agreement aims to manage the distribution of Agamree (vamorolone) in Turkiye, for the treatment of Duchenne muscular dystrophy in patients four years of age and older.
Product Name : Agamree
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 13, 2025
Lead Product(s) : Vamorolone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Santhera Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : SUL-238
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Sulfateq B.V.
Deal Size : Inapplicable
Deal Type : Inapplicable
A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects
Details : SUL-238 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 26, 2024
Lead Product(s) : SUL-238
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Sulfateq B.V.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GN-037
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Monitor CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis
Details : GN-037 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 31, 2023
Lead Product(s) : GN-037
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Monitor CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Patisiran
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Alnylam Pharmaceuticals and Gen Sign Distribution Agreement
Details : Partnership with Gen enables Alnylam to extend access to ONPATTRO to patients suffering from hereditary ATTR amyloidosis with polyneuropathy in Turkey.
Product Name : Onpattro
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
March 25, 2020
Lead Product(s) : Patisiran
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
